Teams 2004 – Phase 1

238 business ideas were submitted in the first phase of »venture» 2004. Of the 43 teams nominated, 10 teams were each awarded CHF 2,500 for the best business idea.

If you would like to get in touch with a team, please contact »venture». After consultation with the team we’ll be happy to facilitate contact.

Winners Phase 1 “business idea” - in alphabetical order:

Alicon, ETH Zürich

ALICON specialises in the development of novel methods of diagnosis and medication for the detection and treatment of neurodegenerative dieseases. In the diagnostic area, ALICON foremost engages in pioneering the development of a first ante mortem BSE test procedure. Owing to the anticipated high sensitivity of this new test procedure and a simple transfer to human beings, adaptations in blood banks are also swiftly realisable. As opposed to presently available Alzheimer medication the beta-inhibitors which are being developed by ALICON do not merely combat the sympotms of the disease but also act directly on its cause. Therefore, these drugs ought to also be applicable in later phases of the disease. Furthermore, they offer the possibility of an effective prophylactic treatment.

CT Sciences, Epalinges VD

CT Sciences (Cancer Therapeutic Sciences) is a drug discovery company developing anti-cancer drugs that show significantly improved efficacy and substantially lower toxicity than current chemotherapeutic compounds. CT Sciences’ proprietary liposome-encapsulation technology offers clear advantages over other available approaches. CT Sciences is currently focusing its research efforts on the development of two anti-cancer drugs for colorectal cancer. Both drugs are at the pre-clinical stage of development. In parallel, CT Sciences has developed a proprietary in vivo target-validation technology based on liposome encapsulation of viral-gene delivery vectors that allows the monitoring of drug delivery in living animal models. The company offers its technology as service- and license-based collaborations to biotechnology and pharmaceutical companies involved in cancer research.

[Foldcore], Stuttgart (D)

[FOLDCORE] is a folded nuclear structure for so-called sandwich materials, which is concealed by two surface layers. Such structures are versatilely deployable: for airplane, truck, rail vehicle, container, funiture and house construction; in formwork elements, accoustic barriers along streets, in discotheques or as ceiling or floor tiles in hospitals and office buildings. Even in the packaging industry, [FOLDCORE] is applicable as a distinctly more efficient alternative to the established corrugated cardboard at comparable manufacturing costs. With this procedure, patent pending, all kinds of materials can inexpensively be folded to a rigid, impact resistant, accoustically dulling structure capable of drainage. The adjustment of the patented procedure to the respective folding material is necessary and basically possible. 

GlycoVaxyn, ETH Zürich

GlycoVaxyn will be active in the life science domain. GlycoVaxyn’s know-how is based on a technology that allows the production of therapeutic glycoproteins in simple cells (Escherichia coli). The proprietary technology can be used as a flexible platform for the development of novel vaccines as well as production strains for large-scale manufacturing of therapeutic glycoproteins. The technology significantly decreases the cost for the production of existing drugs and opens up the possibility for the development of new drugs. GlycoVaxyn will perform contract research for the production and development of therapeutic proteins or vaccines and receive royalties from the sale of the pharmaceutical products. Currently, they have three products ready for testing in vivo and in clinical studies for application.

Jackcontrol, ETH Zürich

Jackcontrol, founded in 2004 as a spin-off company of the Swiss Federal Institute of Technology (Zurich) is an independent, internationally active engineering firm with headquarters in Glarus/Switzerland. The core business of Jackcontrol is in the fields of Pipe Jacking/Microtunneling and the construction of Hydroelectric Power Plants. In both areas Jackcontrol, since its formation, has developed into an innovative, high-performing and reliable partner and today in its core business fields is among the key players.

Lyncée, EPFL Lausanne

Lyncée develops, manufactures and markets innovative imaging systems based on a new technology called Digital Holographic Microscopy (DHM). The system, composed of a microscope and powerful software, enables 3-D nanometric-scale microscopy. And, for the first time, it simultaneously allows imaging, strictly non-invasive observation, and easy-to-perform measurement. Hence, DHM technology is an unrivalled tool for numerous applications in R&D and quality control in manufacturing environments. The DHM technology, a joint development of the EPFL and the University of Lausanne, is protected under two patents in the USA, Europe and Japan. Lyncée has been granted an exclusive worldwide license for the development and commercialization of measuring and imaging devices based on digital holography.

NEUROBAT, Siggenthal Station AG

NEUROBAT is a new generation of intelligent heating- control systems that brings benefits to the entire value chain, from manufacturer to end-user. In terms of energy efficiency, user comfort and simplicity of use it exceeds any controller presently on the market. Additionally, NEUROBAT’s unique self-commissioning feature solves a major industry problem of costly and arduous commissioning. The neural networks of the NEUROBAT heating controller allow it to progressively “learn” and dynamically adapt to the environment, thereby saving energy and maintaining optimal user comfort by avoiding overheating or excessive ventilation rates. The product has already been proven in field trials.

NovoGEL, ETH Zürich

NovoGEL strives to commercially implement a key technology for the production of novel gels, mainly gels based on physical processes, at the ETH Zurich Institute for Polymer Chemistry. The substance class of these new gels opens beneficial new product qualities and production possibilities for many current physical process based applications. Furthermore, new products with extraordinary utility are in posse, such as groceries with a low glycaemic index and high relish. NovoGEL understands itself as an innovative technological enterpriseand as technological hub. Together with cooperation partners and clients it strives to provide its patent and know-how in an ideal application specific form and thus introduce new products to the market.

Permanent Hair Removal, EPFL Lausanne

The removal of unwanted hair is a worldwide issue that represents a multi-billion-dollar market. To date, no conventional depilation method has proven to be satisfactory in terms of the permanency of its effects and its universal effectiveness, as well as its cost, side effects, and the time needed for treatment. Permanent Hair Removal propose a new method for permanent hair removal based on proprietary light-activated dyes that will overcome most of these problems. The product comprises a cream containing the patented dye and a light source, together with a treatment protocol. The target customers are beauty salons for cosmetic depilation as well as medical practices for medical indications.

Phytodiagnostix, EPFL Lausanne

Phytodiagnostix will be a biotechnology company in the agribusiness field, developing crop protection products. Using genetic methods, the company intends to develop biological indicator plants for the early diagnosis of plant virus diseases affecting stone fruits (plums, peaches, nectarines, apricots). These new plants will allow detection of viral infection within a couple of weeks. It is the first time that this technology applied in plants will be used for disease detection. The indicator plants will offer a highly reliable, fast and safe new diagnostic method. Phyto-diagnostix will provide farmers with indicator plant varieties of stone fruits to be planted in the field, allowing a permanent in loco monitoring of crop health status. Engineered indicator plants will be also provided to National Certification Programs for in-greenhouse Plum pox virus (PPV) assessment. The innovative concept, protected by intellectual property rights, gives Phytodia-gnostix the opportunity to enter the agribusiness industry and become a leader in a new area of plant protection.